8-K

­­­­­­­­­­­­­­­­­­­­UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM CORRESPONDENCE

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

July 14, 2011

(Date of the earliest event reported)

Simulations Plus, Inc.

(Exact name of registrant as specified in its charter)

California	001-32046	95-4595609
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

42505 10th Street West, Lancaster, California 93534-7059

(Address of principal executive offices) (Zip Code)

661-723-7723

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

Item 8.01  Other Events

On July 14, 2011, Simulations Plus, Inc., a California corporation (the "Company"), held a conference call reporting its financial result for the third fiscal quarter ended May 31, 2011.

The PowerPoint slides, which were used for this Conference Call, are attached herein as an exhibit.

This report on Form 8-K (the "Report"), including the disclosures set forth herein, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes" and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Report or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the "Commission"), reports to the stockholders of Simulations Plus, Inc., a California corporation (the "Company" or "us," "our" or "we") and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

Item9.01  Financial Statements and Exhibits

(d)  Exhibits

99.1  PowerPoint presentation at the Conference Call on July 14, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SIMULATIONS PLUS, INC.
Dated: July 14, 2011	By:	/s/ Momoko Beran
		Momoko Beran
		Chief Financial Officer

EX-99.1

Exhibit 99.1

Simulations Plus, Inc.

(NASDAQ:SLP)

Third Quarter FY 2011

Conference Call and Webinar

July 14, 2011

With the exception of historical information, the matters discussed in this
presentation are forward-looking statements that involve a number of risks
and uncertainties. The actual results of the Company could differ
significantly from those statements. Factors that could cause or contribute
to such differences include, but are not limited to: continuing demand for
the Company’s products, competitive factors, the Company’s ability to
finance future growth, the Company’s ability to produce and market new
products in a timely fashion, the Company’s ability to continue to attract
and retain skilled personnel, and the Company’s ability to sustain or
improve current levels of productivity. Further information on the
Company’s risk factors is contained in the Company’s quarterly and
annual reports and filed with the Securities and Exchange Commission.

Safe Harbor Statement

•3Q11 compared to 3Q10:

–15th consecutive profitable quarter(37 of last 39 were profitable)

–3Q11 sales up 10.3% to record $3.44 million from $3.12 million

–Pharmaceutical segment sales up 13.5%

–Words+ subsidiary sales up 0.7%

–Net Income up 42.4% to $1.054 million from $0.740 million

–Diluted earnings per share up 49.4% to $0.07 from $0.04

•9moFY11 compared to 9moFY10:

–Sales up 12.9% to Record $9.6 MM from $8.5 MM in 9moFY10

–Pharmaceutical segment sales up 16.3%

–Words+ subsidiary sales up 3.1%

–Net Income up 39.7% to $2.5 million from $1.8 million

–Diluted earnings per share up 43% to $0.16 from $0.11

•Strong balance sheet:

–Cash $9.9 MM at 5/31/11, after using just over $2 million cash repurchase shares
during first two fiscal quarters. Cash today = $10.96 million

–Shareholders’ equity increased 5.8% to $13.8 million from $13.1 million at 9/1/10

–Equity per share increased 8.9% in the first 9 months to $0.86 from $0.79 at 9/1/10

–No debt

SLP 3Q11 Highlights
Three months ended 5/31/11

Consolidated Revenue

Revenue History

Pharmaceutical Growth

Gross Margin (consolidated)

75.6%

78.9%

78.8%

70.4%

73.8%

74.4%

80.0%

67.9%

75.0%

76.3%

77.6%

75.6%

73.6%

77.6%

76.3%

Income Before Taxes

Net Income

$243K

$565K

$764K

$165K

$312K

$368K

$569K

$163K

$430K

$641K

$740K

$345K

$567K

$907K

$1.054 M

Consolidated Income Statement

($ millions)

	3Q11	3Q10
Pharmaceutical software and services revenue	2.640	2.325
Words+ revenue	0.799	0.794
Consolidated revenue	3.439	3.119
Gross profit	2.623	2.420
Gross profit margin	76.3%	77.6%
SG&A	1.063	1.118
R&D	0.238	0.234
Total operating expenses	1.302	1.352
Income before income taxes	1.378	1.112
Net income	1.054	0.740
Earnings per share (diluted)	0.07	0.04

Select Balance Sheet Items

($ millions)

	May 31, 2011	May 31, 2010
Cash and cash equivalents	$9.894	$8.583
Total current assets	13.771	12.335
Total assets	$16.337	$14.566
Total current liabilities	1.747	1.342
Total liabilities	2.529	1.775
Shareholders’ equity	13.808	12.791
Total liabilities and shareholders’ equity	16.337	14.566

Marketing and Sales Program

•Fundamental industry shift continues

–Pharma increasingly utilizing simulation software and modeling tools
to increase productivity - steady stream of scientific meetings

–Software tools are always evolving, and as the technology advances,
new capabilities attract new users.

–Releases during the 3rd quarter included:

–MedChem Studio 2.0

–DDDPlus 4.0

–47 new customers in the first 3 quarters (includes new companies and
new departments within existing large customers)

•Collaborations/Consulting/Grants

–We completed our SBIR grant with the National Institutes of Health.

–We’re progressing on our 5-year collaboration with the FDA Center for
Food Safety and Applied Nutrition to build toxicity models with ADMET
Predictor/Modeler™ for food additives and contaminants

–We recently formed a second studies team for informatics to address
the need for consulting work in cheminformatics (ADMET Predictor &
MedChem Studio) and have already conducted two small studies in
that new area.

•Simulations Plus continues to increase its technological advantage

Ongoing Enhancements

•Version 7.0 was released in August 2010 - a major upgrade

•Three new market-expanding capabilities plus numerous features:

•Drug-to-drug interaction (released, now in beta test for further expansions)

•Ocular drug delivery

•Nasal/pulmonary drug delivery

•Version 5.5 was released in March - major upgrade

•Prediction of sites of metabolism now available

•Version 2.0 was released in April - major upgrade

•Integration of new MedChem Designer software

•Significant speed improvements

•MedChem Designer downloads/activations nearly 800

•Version 4.0 released in June

•Virtual Trials added to show expected variances in experiments

•Customer base continues to grow

•FDA added more licenses during 3rd quarter

Summary

•For the trailing 12 months through May 31:

-Revenues = $11.8 million (up 14.1%)

-Net Income = $2.87 million (up 45.6%)

-Earnings/share = $0.18 (up 45.6%)

•Simulations Plus is globally recognized as a leader in our
respective market niches

-Outstanding reputation for scientific expertise and technological
innovation

-Strong customer support

•Expanding our Life Sciences team:

-To promote faster development of new products and services

-To strengthen our marketing and sales efforts

Q&A